GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (LTS:0JGL) » Definitions » Cyclically Adjusted Price-to-FCF

PCI Biotech Holding ASA (LTS:0JGL) Cyclically Adjusted Price-to-FCF : (As of Jun. 10, 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


PCI Biotech Holding ASA Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for PCI Biotech Holding ASA's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Cyclically Adjusted Price-to-FCF Chart

PCI Biotech Holding ASA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PCI Biotech Holding ASA Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PCI Biotech Holding ASA's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, PCI Biotech Holding ASA's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's Cyclically Adjusted Price-to-FCF falls into.



PCI Biotech Holding ASA Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

PCI Biotech Holding ASA's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, PCI Biotech Holding ASA's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.147/130.4000*130.4000
=-0.147

Current CPI (Jun. 2023) = 130.4000.

PCI Biotech Holding ASA Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201309 -0.548 96.400 -0.741
201312 -0.549 96.600 -0.741
201403 -0.594 97.300 -0.796
201406 -0.783 97.500 -1.047
201409 -0.809 98.500 -1.071
201412 -0.403 98.600 -0.533
201503 -0.522 99.200 -0.686
201506 -0.435 100.100 -0.567
201509 -0.439 100.600 -0.569
201512 -0.257 100.900 -0.332
201603 -0.596 102.500 -0.758
201606 -0.533 103.800 -0.670
201609 -0.643 104.200 -0.805
201612 -0.437 104.400 -0.546
201703 -0.377 105.000 -0.468
201706 -0.339 105.800 -0.418
201709 -0.344 105.900 -0.424
201712 -0.139 106.100 -0.171
201803 -0.479 107.300 -0.582
201806 -0.394 108.500 -0.474
201809 -0.304 109.500 -0.362
201812 -0.265 109.800 -0.315
201903 -0.438 110.400 -0.517
201906 -0.677 110.600 -0.798
201909 -0.495 111.100 -0.581
201912 -0.528 111.300 -0.619
202003 -0.589 111.200 -0.691
202006 -0.444 112.100 -0.516
202009 -0.602 112.900 -0.695
202012 -0.429 112.900 -0.495
202103 -0.543 114.600 -0.618
202106 -0.401 115.300 -0.454
202109 -0.352 117.500 -0.391
202112 -0.464 118.900 -0.509
202203 -0.578 119.800 -0.629
202206 -0.487 122.600 -0.518
202209 -0.237 125.600 -0.246
202212 -0.280 125.900 -0.290
202303 -0.144 127.600 -0.147
202306 -0.147 130.400 -0.147

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PCI Biotech Holding ASA  (LTS:0JGL) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


PCI Biotech Holding ASA Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA (LTS:0JGL) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (LTS:0JGL) Headlines

No Headlines